EUVIMEDEUVIMED entdecken
Open Access

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank

Hyun-Seok Kim, Mohammad Saeid Rezaee-Zavareh, Yufeng Wang, Abdelrahman M Attia, Minsun Kwak, Seungwon Burm, Derin Celtik, Daniel Legaspi, Osama Khattab, Naomy Kim, Beza M Mengistu, Kelsey N Larios und 11 weitere

Clinical Gastroenterology and Hepatology · 2026-07

DOI: 10.1016/j.cgh.2026.04.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-07. Verfasst von Hyun-Seok Kim und 22 weiteren Autor:innen. Beteiligte Einrichtung: Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: hyunseok.kim@cshs.org. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Coffee consumption has been linked to a reduced risk of liver disease, but large-scale prospective studies integrating imaging biomarkers, proteomics, and intake patterns remain limited. The effects of coffee type, additives, and metabolic modifiers are also unclear. METHODS: We analyzed 354,957 UK Biobank participants without baseline cirrhosis or hepatocellular carcinoma. Coffee consumption, type (caffeinated/decaffeinated), and additives (sugar/sweeteners) were assessed by questionnaire. Incident cirrhosis, hepatocellular carcinoma, and liver-related mortality were ascertained through linked records. In a subcohort (n = 28,961) undergoing magnetic resonance imaging, hepatic fat (proton density fat fraction), iron, and fibroinflammation (iron-corrected T1) were evaluated. Proteomic profiling (n = 44,633) used Olink assays. Models were adjusted for demographic, behavioral, metabolic, and genetic covariates. RESULTS: Over a median 13-year follow-up, higher coffee intake showed a graded reduction in liver outcomes, with ≥5 cups/day group having risk reductions of cirrhosis (hazard ratio, 0.68; 95% confidence interval, 0.58-0.79), hepatocellular carcinoma (hazard ratio, 0.53; 95% confidence interval, 0.34-0.83), and liver-related mortality (hazard ratio, 0.58; 95% confidence interval, 0.45-0.74). Protective associations were similar for caffeinated and decaffeinated coffee and persisted among those adding sugar or artificial sweeteners, although additive use correlated with modestly higher iron-corrected T1. Higher coffee intake corresponded to lower hepatic fat, iron, and fibroinflammation. Proteomic analysis revealed consistent patterns: higher levels of hepatocellular synthesis and complement proteins (transthyretin, selenoprotein P, complement factor H-related protein4/5) and lower levels of fibrogenic and macrophage-activation markers (microfibril-associated protein 4, colony stimulating factor 1 receptor, ectonucleotide pyrophosphatase/phosphodiesterase 2, transthyretin) with coffee drinking. CONCLUSIONS: Higher coffee intake was associated with favorable clinical, imaging, and proteomic indicators of liver health. These multidimensional findings support moderate unsweetened coffee as a simple strategy for liver disease prevention.

Schlagwörter

Stichwörter der Autor:innen

CirrhosisCoffee ConsumptionHepatocellular CarcinomaLiver DiseaseUK Biobank

Autor:innen und Institutionen

  • Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: hyunseok.kim@cshs.org.
  • Middle East Liver Diseases (MELD) Center, Tehran, Iran.
  • Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California.
  • University of California Los Angeles Medical School, Los Angeles, California; Department of Gastroenterology and Hepatology, University of Southern California, Los Angeles, California.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Roudebush Veterans Administration Medical Center, Indianapolis, Indiana.

Förderung

  • NIAAA NIH HHS
  • NIH

Zitieren

APA

Kim, H. S., Rezaee-Zavareh, M. S., Wang, Y., Attia, A. M., Kwak, M., Burm, S., Celtik, D., Legaspi, D., Khattab, O., Kim, N., Mengistu, B. M., Larios, K. N., Kim, D. S., Ayoub, W., Kuo, A., Martin, P., Vipani, A., Wang, Y., Liangpunsakul, S., …, & Yang, J. D. (2026). Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.035

Vancouver

Kim HS, Rezaee-Zavareh MS, Wang Y, Attia AM, Kwak M, Burm S, et al. Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.035

BibTeX
@article{Kim2026,
  author = {Kim, Hyun-Seok and Rezaee-Zavareh, Mohammad Saeid and Wang, Yufeng and Attia, Abdelrahman M and Kwak, Minsun and Burm, Seungwon and Celtik, Derin and Legaspi, Daniel and Khattab, Osama and Kim, Naomy and Mengistu, Beza M and Larios, Kelsey N and Kim, David Sooik and Ayoub, Walid and Kuo, Alexandar and Martin, Paul and Vipani, Aarshi and Wang, Yun and Liangpunsakul, Suthat and Li, Debiao and Lu, Shelly C and Pandol, Stephen and Yang, Ju Dong},
  title = {Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.04.035}
}
Kostenlos starten →